A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
A phase 3 trial of Amivantamab, Pembrolizumab, Carboplatin and Cisplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer is a phase 3 interventional study registered as NCT07276399 by Janssen Research & Development, LLC, with 500 participants planned, started 2025-12-03 and due to reach its primary completion in 2029-06-18. Interventions recorded: Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil and Cisplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Shares Amivantamab, Johnson & Johnson, Carboplatin, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Shares Amivantamab, Johnson & Johnson, Carboplatin and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
Shares Cisplatin, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialEfficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
Shares Cisplatin, Head and neck squamous cell carcinoma and the tag pipeline.